Efthymia Giannitsioti, Mauro José Salles, Andreas Mavrogenis, Dolors Rodriguez-Pardo, Ibai Los-Arcos, Alba Ribera, Javier Ariza, María Dolores Del Toro, Sophie Nguyen, Eric Senneville, Eric Bonnet, Monica Chan, Maria Bruna Pasticci, Sabine Petersdorf, Natividad Benito, Nuala O' Connell, Antonio Blanco García, Gábor Skaliczki, Pierre Tattevin, Zeliha Kocak Tufan, Nikolaos Pantazis, Panayiotis D Megaloikonomos, Panayiotis Papagelopoulos, Alejandro Soriano, Antonios Papadopoulos, The Esgiai Collaborators Study Group
{"title":"多药耐药和广泛耐药革兰氏阴性菌引起的下肢骨合成相关感染:一项多中心队列研究","authors":"Efthymia Giannitsioti, Mauro José Salles, Andreas Mavrogenis, Dolors Rodriguez-Pardo, Ibai Los-Arcos, Alba Ribera, Javier Ariza, María Dolores Del Toro, Sophie Nguyen, Eric Senneville, Eric Bonnet, Monica Chan, Maria Bruna Pasticci, Sabine Petersdorf, Natividad Benito, Nuala O' Connell, Antonio Blanco García, Gábor Skaliczki, Pierre Tattevin, Zeliha Kocak Tufan, Nikolaos Pantazis, Panayiotis D Megaloikonomos, Panayiotis Papagelopoulos, Alejandro Soriano, Antonios Papadopoulos, The Esgiai Collaborators Study Group","doi":"10.5194/jbji-7-279-2022","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose</b>: The purpose of this study was the clinical and therapeutic assessment of lower-limb osteosynthesis-associated infection (OAI) by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria (GNB), which have been poorly studied to date. <b>Methods</b>: A prospective multicentre observational study was conducted on behalf of ESGIAI (the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group on Implant-Associated Infections). Factors associated with remission of the infection were evaluated by multivariate and Cox regression analysis for a 24-month follow-up period. <b>Results</b>: Patients ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>57</mn></mrow> </math> ) had a history of trauma (87.7 %), tumour resection (7 %) and other bone lesions (5.3 %). Pathogens included <i>Escherichia coli</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>16</mn></mrow> </math> ), <i>Pseudomonas aeruginosa</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>14</mn></mrow> </math> ; XDR 50 %), <i>Klebsiella</i> spp. ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>7</mn></mrow> </math> ), <i>Enterobacter</i> spp. ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>9</mn></mrow> </math> ), <i>Acinetobacter</i> spp. ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>5</mn></mrow> </math> ), <i>Proteus mirabilis</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>3</mn></mrow> </math> ), <i>Serratia marcescens</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>2</mn></mrow> </math> ) and <i>Stenotrophomonas maltophilia</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>1</mn></mrow> </math> ). The prevalence of ESBL (extended-spectrum <math><mi>β</mi></math> -lactamase), fluoroquinolone and carbapenem resistance were 71.9 %, 59.6 % and 17.5 % respectively. Most patients ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>37</mn></mrow> </math> ; 64.9 %) were treated with a combination including carbapenems ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>32</mn></mrow> </math> ) and colistin ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>11</mn></mrow> </math> ) for a mean of 63.3 d. Implant retention with debridement occurred in early OAI (66.7 %), whereas the infected device was removed in late OAI (70.4 %) ( <math><mrow><mi>p</mi> <mo>=</mo> <mn>0.008</mn></mrow> </math> ). OAI remission was achieved in 29 cases (50.9 %). The type of surgery, antimicrobial resistance and duration of treatment did not significantly influence the outcome. Independent predictors of the failure to eradicate OAI were age <math><mrow><mo>></mo> <mn>60</mn></mrow> </math> years (hazard ratio, HR, of 3.875; 95 % confidence interval, CI95 %, of 1.540-9.752; <math><mrow><mi>p</mi> <mo>=</mo> <mn>0.004</mn></mrow> </math> ) and multiple surgeries for OAI (HR of 2.822; CI95 % of 1.144-6.963; <math><mrow><mi>p</mi> <mo>=</mo> <mn>0.024</mn></mrow> </math> ). <b>Conclusions</b>: Only half of the MDR/XDR GNB OAI cases treated by antimicrobials and surgery had a successful outcome. Advanced age and multiple surgeries hampered the eradication of OAI. Optimal therapeutic options remain a challenge.</p>","PeriodicalId":15271,"journal":{"name":"Journal of Bone and Joint Infection","volume":"7 6","pages":"279-288"},"PeriodicalIF":1.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832304/pdf/jbji-7-279.pdf","citationCount":"0","resultStr":"{\"title\":\"Osteosynthesis-associated infection of the lower limbs by multidrug-resistant and extensively drug-resistant Gram-negative bacteria: a multicentre cohort study.\",\"authors\":\"Efthymia Giannitsioti, Mauro José Salles, Andreas Mavrogenis, Dolors Rodriguez-Pardo, Ibai Los-Arcos, Alba Ribera, Javier Ariza, María Dolores Del Toro, Sophie Nguyen, Eric Senneville, Eric Bonnet, Monica Chan, Maria Bruna Pasticci, Sabine Petersdorf, Natividad Benito, Nuala O' Connell, Antonio Blanco García, Gábor Skaliczki, Pierre Tattevin, Zeliha Kocak Tufan, Nikolaos Pantazis, Panayiotis D Megaloikonomos, Panayiotis Papagelopoulos, Alejandro Soriano, Antonios Papadopoulos, The Esgiai Collaborators Study Group\",\"doi\":\"10.5194/jbji-7-279-2022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose</b>: The purpose of this study was the clinical and therapeutic assessment of lower-limb osteosynthesis-associated infection (OAI) by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria (GNB), which have been poorly studied to date. <b>Methods</b>: A prospective multicentre observational study was conducted on behalf of ESGIAI (the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group on Implant-Associated Infections). Factors associated with remission of the infection were evaluated by multivariate and Cox regression analysis for a 24-month follow-up period. <b>Results</b>: Patients ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>57</mn></mrow> </math> ) had a history of trauma (87.7 %), tumour resection (7 %) and other bone lesions (5.3 %). Pathogens included <i>Escherichia coli</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>16</mn></mrow> </math> ), <i>Pseudomonas aeruginosa</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>14</mn></mrow> </math> ; XDR 50 %), <i>Klebsiella</i> spp. ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>7</mn></mrow> </math> ), <i>Enterobacter</i> spp. ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>9</mn></mrow> </math> ), <i>Acinetobacter</i> spp. ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>5</mn></mrow> </math> ), <i>Proteus mirabilis</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>3</mn></mrow> </math> ), <i>Serratia marcescens</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>2</mn></mrow> </math> ) and <i>Stenotrophomonas maltophilia</i> ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>1</mn></mrow> </math> ). The prevalence of ESBL (extended-spectrum <math><mi>β</mi></math> -lactamase), fluoroquinolone and carbapenem resistance were 71.9 %, 59.6 % and 17.5 % respectively. Most patients ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>37</mn></mrow> </math> ; 64.9 %) were treated with a combination including carbapenems ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>32</mn></mrow> </math> ) and colistin ( <math><mrow><mi>n</mi> <mo>=</mo> <mn>11</mn></mrow> </math> ) for a mean of 63.3 d. Implant retention with debridement occurred in early OAI (66.7 %), whereas the infected device was removed in late OAI (70.4 %) ( <math><mrow><mi>p</mi> <mo>=</mo> <mn>0.008</mn></mrow> </math> ). OAI remission was achieved in 29 cases (50.9 %). The type of surgery, antimicrobial resistance and duration of treatment did not significantly influence the outcome. Independent predictors of the failure to eradicate OAI were age <math><mrow><mo>></mo> <mn>60</mn></mrow> </math> years (hazard ratio, HR, of 3.875; 95 % confidence interval, CI95 %, of 1.540-9.752; <math><mrow><mi>p</mi> <mo>=</mo> <mn>0.004</mn></mrow> </math> ) and multiple surgeries for OAI (HR of 2.822; CI95 % of 1.144-6.963; <math><mrow><mi>p</mi> <mo>=</mo> <mn>0.024</mn></mrow> </math> ). <b>Conclusions</b>: Only half of the MDR/XDR GNB OAI cases treated by antimicrobials and surgery had a successful outcome. Advanced age and multiple surgeries hampered the eradication of OAI. Optimal therapeutic options remain a challenge.</p>\",\"PeriodicalId\":15271,\"journal\":{\"name\":\"Journal of Bone and Joint Infection\",\"volume\":\"7 6\",\"pages\":\"279-288\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832304/pdf/jbji-7-279.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bone and Joint Infection\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5194/jbji-7-279-2022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Joint Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5194/jbji-7-279-2022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Osteosynthesis-associated infection of the lower limbs by multidrug-resistant and extensively drug-resistant Gram-negative bacteria: a multicentre cohort study.
Purpose: The purpose of this study was the clinical and therapeutic assessment of lower-limb osteosynthesis-associated infection (OAI) by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria (GNB), which have been poorly studied to date. Methods: A prospective multicentre observational study was conducted on behalf of ESGIAI (the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group on Implant-Associated Infections). Factors associated with remission of the infection were evaluated by multivariate and Cox regression analysis for a 24-month follow-up period. Results: Patients ( ) had a history of trauma (87.7 %), tumour resection (7 %) and other bone lesions (5.3 %). Pathogens included Escherichia coli ( ), Pseudomonas aeruginosa ( ; XDR 50 %), Klebsiella spp. ( ), Enterobacter spp. ( ), Acinetobacter spp. ( ), Proteus mirabilis ( ), Serratia marcescens ( ) and Stenotrophomonas maltophilia ( ). The prevalence of ESBL (extended-spectrum -lactamase), fluoroquinolone and carbapenem resistance were 71.9 %, 59.6 % and 17.5 % respectively. Most patients ( ; 64.9 %) were treated with a combination including carbapenems ( ) and colistin ( ) for a mean of 63.3 d. Implant retention with debridement occurred in early OAI (66.7 %), whereas the infected device was removed in late OAI (70.4 %) ( ). OAI remission was achieved in 29 cases (50.9 %). The type of surgery, antimicrobial resistance and duration of treatment did not significantly influence the outcome. Independent predictors of the failure to eradicate OAI were age years (hazard ratio, HR, of 3.875; 95 % confidence interval, CI95 %, of 1.540-9.752; ) and multiple surgeries for OAI (HR of 2.822; CI95 % of 1.144-6.963; ). Conclusions: Only half of the MDR/XDR GNB OAI cases treated by antimicrobials and surgery had a successful outcome. Advanced age and multiple surgeries hampered the eradication of OAI. Optimal therapeutic options remain a challenge.